Literature DB >> 9760094

Amphetamine derivative fatalities in South Australia--is "Ecstasy" the culprit?

R W Byard1, J Gilbert, R James, R J Lokan.   

Abstract

OBJECTIVE: To analyze features of a series of fatalities caused by amphetamine-derivative designer drugs marketed as "Ecstasy" in South Australia, and to identify reasons for the recent marked increase in number of these deaths.
MATERIALS AND METHODS: Following the death of a 26-year-old woman after alleged ingestion of Ecstasy tablets, a retrospective search of files at State Forensic Science, Adelaide and the South Australian State Coroner's Department was undertaken from February 1992 to January 1997 to identify similar cases.
RESULTS: Six fatalities were found, all of which have occurred since September 1995 (M:F ratio, 1:1; age range, 22 to 36 years; average age, 27.7 years). All individuals had histories of recent ingestion of illegal drugs thought to be Ecstasy (methylenedioxymethamphetamine, MDMA) at the time of purchase. Delay occurred in seeking medical attention, despite severe symptoms. Causes of death involved documented hyperthermia in 3 cases (temperatures of 41.5-46.1 degrees C), with features of hyperthermia in one other case, and intracranial hemorrhage in another. Drugs in toxic/lethal amounts identified at postmortem included paramethoxyamphetamine (PMA) in all cases, amphetamine/methamphetamine in 4 cases, and methylenedioxymethamphetamine (MDMA or Ecstasy) in only 2 cases. Interaction with a prescription medication (fluoxetine) may have occurred in 1 case.
CONCLUSIONS: The number of deaths due to amphetamine derivatives apparently due to substitution of PMA for MDMA (Ecstasy) have recently increased markedly in Adelaide. Potential users should be warned that PMA has been associated with a much higher rate of lethal complications than other designer drugs, and that no guarantee can be made that tablets sold as Ecstasy are not PMA.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9760094     DOI: 10.1097/00000433-199809000-00013

Source DB:  PubMed          Journal:  Am J Forensic Med Pathol        ISSN: 0195-7910            Impact factor:   0.921


  12 in total

Review 1.  Ten years of 'ecstasy'.

Authors:  C M Milroy
Journal:  J R Soc Med       Date:  1999-02       Impact factor: 5.344

Review 2.  Street drug abuse leading to critical illness.

Authors:  Babak Mokhlesi; Prasad S Garimella; Aaron Joffe; Valerie Velho
Journal:  Intensive Care Med       Date:  2004-03-04       Impact factor: 17.440

3.  Herbal medicines and forensic investigations.

Authors:  Roger W Byard; Ian Musgrave
Journal:  Forensic Sci Med Pathol       Date:  2010-06       Impact factor: 2.007

4.  Diagnostic yield and characteristic features in a series of decomposed bodies subject to coronial autopsy.

Authors:  Roger W Byard; Emily Farrell; Ellie Simpson
Journal:  Forensic Sci Med Pathol       Date:  2007-08-07       Impact factor: 2.007

5.  Issues in the interpretation of postmortem toxicology.

Authors:  Roger W Byard; Danielle M Butzbach
Journal:  Forensic Sci Med Pathol       Date:  2012-09       Impact factor: 2.007

6.  An announced suicide with ecstasy.

Authors:  Kathrin Libiseller; Marion Pavlic; Petra Grubwieser; Walter Rabl
Journal:  Int J Legal Med       Date:  2005-09-21       Impact factor: 2.686

Review 7.  The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs.

Authors:  H Kalant
Journal:  CMAJ       Date:  2001-10-02       Impact factor: 8.262

8.  "Ecstasy" associated deaths: what is a fatal concentration ? Analysis of a case series.

Authors:  C M Milroy
Journal:  Forensic Sci Med Pathol       Date:  2011-01-25       Impact factor: 2.007

Review 9.  Hyponatremia at autopsy: an analysis of etiologic mechanisms and their possible significance.

Authors:  Angela Byramji; Glenda Cains; John D Gilbert; Roger W Byard
Journal:  Forensic Sci Med Pathol       Date:  2008-06-12       Impact factor: 2.007

Review 10.  A bitter pill. Overview of ecstasy (MDMA, MDA) related fatalities.

Authors:  Fabrizio Schifano
Journal:  Psychopharmacology (Berl)       Date:  2003-12-13       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.